Home Diagnostics, Inc. (NASDAQ: HDIX) climbed 88.93% to $11.43 in the pre-market session. Home Diagnostics announced today that it has signed a definitive merger agreement with Nipro Corporation. In the previous trading session, HDIX closed at $6.05. HDIX has declined over 13% in the last year.

Acme Packet, Inc. (NASDAQ: APKT) jumped 17.99% to $12.59 in the pre-market session. Acme Packet reported yesterday that it expects total revenues to be in the range of $182 million - $186 million, up from prior outlook of $166 million - $168 million and expects non-GAAP diluted earnings per share to be in the range of $0.44 - $0.47, up from prior outlook of $0.41 - $0.42. The 52-week trading range for APKT is $3.96 - $12.25. Acme Packet closed at $10.67 in the last trading session.

Labopharm Inc. (NASDAQ: DDSS) moved up 19.54% to $3.12 after Labopharm announced today that the U.S. Food and Drug Administration has approved OLEPTRO(TM) used for the treatment of major depressive disorder in adults. The 52-week trading range for DDSS is $0.76 - $2.95. Labopharm closed at $2.61 in the previous trading session. DDSS has gained over 31% in the last six months.

Dataram Corporation (NASDAQ: DRAM) surged 11.42% to $3.22 in the pre-market session. In the last trading session, Dataram Corporation closed at $2.89. The 52-week trading range for Dataram Corporation is $1.11 - $5.49. DRAM has surged over 99% in the last six months.

NetLogic Microsystems, Inc. (NASDAQ: NETL) climbed 10.82% to $48.02 in the pre-market session after NetLogic Microsystems announced yesterday a fourth quarter revenue of $69.5 million, as compared to $30.9 million in the year ago period. NetLogic Microsystems closed at $43.33 in the last trading session. In the last year, NETL has gained over 104%.

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) increased 8.62% to $30.50 after Auxilium Pharmaceuticals announced yesterday that it has received marketing approval from the U.S. Food and Drug Administration for XIAFLEX, used for the treatment of adult Dupuytren's contracture patients with a palpable cord. The 52-week trading range for AUXL is $21.85 - $37.28. In the previous trading session, Auxilium Pharmaceuticals closed at $28.08.

In his The Coolcat Report, small cap expert Kevin Kennedy looks to Dataram (NASDAQ: DRAM) as his top speculative idea for the coming year.

"Dataram is a small company with growing revenues and a market cap of less than $30 million. Founded in 1967, Dataram manufactures computer memory, storage and software products.

"Its products and services deliver IT infrastructure optimization, dramatically increase application performance and deliver substantial cost savings.

"Dataram solutions are deployed in 70 Fortune 100 companies and in mission-critical government and defense applications around the world.

"Second-quarter revenues reported in late November were $10.7 million, up 51% from the $7.1 million reported in the same quarter in the prior year. The company lost $1.6 million, or $0.18 per share.

"Demand and memory pricing is improving, and the company’s recently acquired Micro Memory Bank business unit is boosting sales and new products.

"The company also has high hopes for its recently introduced storage area network (SAN) optimization solution called XcelaSAN, which is expected to be available in early 2010. Sales of that product and lower expected R&D expenses going forward should push the company towards profitability.

"The company’s stock broke out of nine-week base on big volume Nov. 20, but has fallen back from above $5 to the low $3 range. It looks well priced at these levels."

A Taiwanese research group has turned to RRAM (Resistive-RAM) as the latest possible Holy Grail of memory chips, one that can replace both DRAM and NAND flash memory.